Susan Lacy
About Susan Lacy
Susan Lacy is the Senior Director of Integrative Sciences Oncology at Bristol Myers Squibb, with extensive experience in drug discovery and a background in biochemistry and molecular biology.
Current Role at Bristol Myers Squibb
Susan Lacy currently holds the position of Senior Director, Integrative Sciences Oncology at Bristol Myers Squibb. She is based in Redwood City, California, United States. Her role involves actively evaluating and aligning new technologies, modalities, and platforms to enhance Oncology drug discovery. She is recognized for integrating disruptive technologies into research strategies and establishing multidisciplinary teams to drive drug discovery initiatives.
Previous Role at Sonoma Biotherapeutics
Before joining Bristol Myers Squibb, Susan Lacy served as Vice President of Discovery at Sonoma Biotherapeutics. She held this position from 2020 to 2021, operating out of South San Francisco, California, United States.
Career at AbbVie
Susan Lacy worked at AbbVie for 11 years, from 2009 to 2020. She held the position of Director, Immuno-Oncology Drug Discovery in Redwood City, California, United States. During her tenure, she was involved in generating novel therapeutics aimed at clinical development and led multidisciplinary teams in drug discovery.
Experience at Abbott
From 2000 to 2009, Susan Lacy worked at Abbott in Worcester, Massachusetts. She served as Senior Group Leader/Senior Scientist I/II in the Global Biologics division. During her 9-year tenure, she contributed to biologics research and development.
Academic Background
Susan Lacy holds a PhD in Molecular Biology, Cancer, and Genetics from McMaster University, which she completed from 1986 to 1991. She also earned a Bachelor of Science (B.Sc.) in Biochemistry from the University of New Brunswick, where she studied from 1991 to 1997. Additionally, she was a Howard Hughes Postdoctoral Fellow at Harvard Medical School, based in Boston Children's Hospital, from 1997 to 2000.